1. Home
  2. MX vs ENGN Comparison

MX vs ENGN Comparison

Compare MX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnachip Semiconductor Corporation

MX

Magnachip Semiconductor Corporation

HOLD

Current Price

$3.72

Market Cap

139.1M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.80

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MX
ENGN
Founded
2003
1999
Country
South Korea
Canada
Employees
N/A
82
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
139.1M
117.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
MX
ENGN
Price
$3.72
$1.80
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$5.75
$21.08
AVG Volume (30 Days)
1.0M
782.8K
Earning Date
04-28-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
43.06
N/A
EPS
N/A
N/A
Revenue
$178,860,000.00
N/A
Revenue This Year
$8.55
N/A
Revenue Next Year
$6.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$1.40
52 Week High
$9.86
$12.25

Technical Indicators

Market Signals
Indicator
MX
ENGN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MX
ENGN

About MX Magnachip Semiconductor Corporation

MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: